Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the <scp>FDA</scp> adverse event reporting system (<scp>FAERS</scp>) from 2022 to 2023
Hannah Godfrey, Zachary Leibovit‐Reiben, Patrick Jedlowski, Rebecca Thiede
Abstract
The data that support the findings of this study are openly available in the Food and Drug Administration Adverse Event Reporting System at https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.
Topics & Concepts
Adverse Event Reporting SystemAdverse effectSemaglutideEvent (particle physics)MedicinePharmacologyEndocrinologyQuantum mechanicsLiraglutideType 2 diabetesPhysicsDiabetes mellitusColorectal Cancer Treatments and StudiesChemotherapy-related skin toxicityHair Growth and Disorders